Trial Search Results
A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
To provide Therasphere treatment for patients diagnosed with unresectable liver cancer.
Stanford is currently accepting patients for this trial.
Collaborator: BTG International Inc.
- Device: Therasphere
Patients of any age, of any race or sex, who have hepatocellular carcinoma of the liver,
and who are able to give informed consent, will be eligible. Patients must have an ECOG
Performance Status score of = 2, with a life expectancy of >/= 3 months, non-pregnant
with an acceptable contraception in premenopausal women. Patients must be >4 weeks since
prior radiation or prior surgery and at least 1 month post other chemotherapy.
- Contraindications to angiography and selective visceral catheterization
- Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of
radiation to the lungs
- Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after
application of established angiographic techniques to stop or mitigate such flow (ex.
placing catheter distal to gastric vessels)
- Significant extrahepatic disease representing an imminent life-threatening outcome
- Severe liver dysfunction or pulmonary insufficiency
- Active uncontrolled infection
- Significant underlying medical or psychiatric illness
Patients will be excluded: if they have a co-morbid disease or an acute or chronic
condition that would preclude safe delivery of TheraSphere treatment and place the patient
at undue risk.
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study